CAAS Capital Management’s Kestra Medical Technologies KMTS Stock Holding History

CAAS Capital Management’s Portfolio KMTS Stock Details KMTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.47M	Buy	+59,000	New	+$1.36M	0.16%	139

Other funds holding KMTS

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

CAAS Capital Management's KMTS Position: Q1 2025 in Review

CAAS Capital Management opened a new position in Kestra Medical Technologies (KMTS) in Q1 2025: 59,000 shares worth $1.47M. The stake represents 0.16% of the portfolio and ranks #139 among its holdings.

63 funds tracked by Wall St. Rank hold KMTS as of Q1 2025.

CAAS Capital Management held 59,000 shares of Kestra Medical Technologies worth $1.47M as of Q1 2025.
Kestra Medical Technologies was a new CAAS Capital Management position in Q1 2025.
Kestra Medical Technologies made up 0.16% of CAAS Capital Management's portfolio in Q1 2025, its #139 holding.
63 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.